St. John’s Wort and Drug Interactions Revisited Part 2

By Donnie Yance

St. John’s Wort: A Case Study In The Power of Synergy

St. John’s Wort contains a complex array of bioactive compounds including flavonoids, hyperforin, and hypericin. What’s fascinating is that no single compound proves superior to the whole plant extract.¹ This exemplifies why I’m such an advocate for synergistic formulations—nature has already done the hard work of creating balanced, effective combinations.

St. John’s wort exemplifies the potential for herbal-pharmaceutical synergy in cancer care. While traditionally known for mood support, emerging research suggests this herb may enhance certain cancer treatments through multiple mechanisms:

• Enhanced drug metabolism: St. John’s wort can influence how the body processes conventional cancer drugs
• Immune system modulation: The herb may support the body’s natural cancer-fighting mechanisms
• Oxidative stress reduction: Its antioxidant properties could help protect healthy cells during treatment

However, St. John’s wort also demonstrates the complexity of herb-drug interactions, as it can both enhance and interfere with conventional medications depending on timing, dosage, and liver enzyme pathway overlap.

My Clinical Approach: Strategic Combinations

In my practice, I’ve found that the synergy of plants and nutritional compounds creates the most effective combinations. I regularly incorporate St. John’s Wort into blended formulas designed to support mood, combat stress, and enhance cognitive function, combining it with:

• Ashwagandha (Withania somnifera) – for stress adaptation
• Magnolia (Magnolia officinalis) Bark Extract – for emotional balance
• N-Acetyl-L-Tyrosine – for neurotransmitter support
• L-Tryptophan – for serotonin production

Pharmacological Mechanisms of Drug Interactions Regarding St. John’s Wort Extracts

Studies show that St. John’s Wort can affect how the body processes certain medications. It speeds up the breakdown and removal of these drugs by increasing the activity of liver and intestinal enzymes (especially one called CYP 3A4) and a drug-transporting protein called P-glycoprotein.

This effect is mainly due to a molecule in St. John’s Wort called hyperforin. Hyperforin activates a protein in the body called the pregnane X receptor (PXR), which then triggers the body to produce more of the enzymes and proteins that clear drugs out of the system. This can make some medications less available to the body when taken with St. John’s Wort.

Clinical Case Studies: Cyclosporine Interactions

Liver Transplant Case

Several case studies have highlighted the clinical significance of interactions between cyclosporine and SJW. Cyclosporine is a drug primarily used as an immunosuppressant to prevent organ transplant rejection by the immune system. Clinical awareness of this interaction intensified following a case involving a 63-year-old liver transplant patient. Fourteen months post-transplantation, this patient developed severe acute rejection associated with an unexpected decrease in cyclosporine levels. The patient had initiated SJW treatment (2 × 900 mg daily) for increasing depressive episodes two weeks prior to the transplantation.

Subsequent cyclosporine dosage increases led to adverse drug reactions (ADRs). Assessment of oral cyclosporine absorption suggested enhanced metabolism. When SJW intake was discontinued, cyclosporine blood levels recovered.²

Cardiac Transplant Cases

Two cases of acute heart transplant rejection associated with a specific SJW preparation further emphasized the clinical significance of this drug interaction. In both instances, daily administration of 900 mg commercial SJW extract preceded decreased cyclosporine levels in previously stable patients, resulting in acute heart transplant rejection confirmed by endomyocardial biopsy. Cyclosporine concentrations returned to therapeutic ranges when patients discontinued SJW.³

Renal Transplant Cases

Nearly identical scenarios occurred in two separate case reports involving renal transplant patients who developed subtherapeutic cyclosporine concentrations associated with SJW preparations at recommended doses.⁴ In both cases, cyclosporine concentrations normalized after SJW discontinuation.

Hyperforin Content and Clinical Relevance

Notably, all cases involving clinically relevant pharmacokinetic interactions involved St John’s Wort preparations rich in hyperforin. For products containing low hyperforin content, no clinically relevant pharmacokinetic drug interactions have been reported.

Collectively, data on pharmacokinetic interactions with SJW preparations correlate directly with daily hyperforin dosage. Induction of PXR-related metabolic enzymes and transporters cannot be excluded at daily dosages exceeding 1 mg hyperforin. To minimize pharmacokinetic interactions and enhance SJW product safety, low-hyperforin extracts should be recommended for therapeutic use. At daily dosages of maximum 1 mg hyperforin, no clinically relevant pharmacokinetic interactions are anticipated.⁵,⁶

St. John’s Wort Extract (SJWE) and Cancer

SJWE demonstrates broad anti-cancer activity across multiple cancer types, including brain cancers (glioblastoma, neuroblastoma), blood cancers (leukemia), and solid tumors of the liver, breast, prostate, lung, bladder, colon, skin, and pancreas. The herb’s anti-cancer mechanisms work through two primary pathways: inducing programmed cell death (apoptosis) by activating caspase enzymes, and directly inhibiting cancer cell proliferation. Laboratory studies have consistently confirmed these cytotoxic effects across various cancer cell lines in controlled in vitro experiments.⁷

St. John’s Wort Extract (SJWE) Enhances the Antitumor Efficacy of 5-Florouracil (5-FU) While Reducing Toxicity

A study was conducted that demonstrated that the SJW extract significantly enhanced the tumor inhibition rate of 5-FU, improved the immune function, reduced the toxic effects, and prolonged the survival time in tumor-bearing mice.⁸

St. John’s Wort Extract (SJWE) and Irinotecan (CPT-11) Metabolism

A study from 2002 showed how St. John’s Wort extract (SJWE) affects the way the body processes the chemotherapy drug Irinotecan in five cancer patients. It used a study design where each patient received both treatments at different times. Irinotecan works by blocking an enzyme called topoisomerase. When patients took St. John’s Wort (900 mg daily for 18 days), the amount of the drug’s active form (called SN-38) in their blood dropped by 42%. This meant they experienced fewer side effects like damage to their bone marrow (myelosuppression) than when they took Irinotecan alone.⁹

How serious these kinds of drug interactions are can depend on many things—such as how much hyperforin is in the St. John’s Wort extract, the dose and timing of both the herb and the drug, and how the drug is given.^10,11

Supporting Research Studies

Study I: Toxicity Reduction

CPT-11 is a drug used to treat colon cancer by blocking an enzyme called topoisomerase I, which helps cancer cells grow. A study looked at how taking St. John’s Wort (SJW) along with CPT-11 affects the drug’s side effects and how it’s processed in the body. Researchers studied rats that were given either SJW or a placebo before being treated with CPT-11. Rats that only got CPT-11 lost weight quickly, but those that also received SJW lost less weight. SJW also helped reduce some of the common side effects of CPT-11, such as stomach problems and blood-related issues. ¹²

Study II: Anti-inflammatory Effects

Diarrhea is a common and serious side effect of many chemotherapy drugs, including irinotecan (CPT-11), 5-fluorouracil, oxaliplatin, capecitabine, and raltitrexed. St. John’s Wort (SJW), an herb known for its anti-inflammatory properties, has shown promise in early studies for reducing diarrhea caused by irinotecan. In this study, researchers tested whether SJW could affect certain inflammation-related proteins—called cytokines—like IL-1β, IL-2, IL-6, IFN-γ, and TNF-α, as well as prevent cell death in the intestines of rats. The rats were given irinotecan for 4 days and SJW (or a placebo) for 8 days, and researchers monitored their diarrhea, weight loss, tissue damage, and inflammation over 11 days.

The results showed that SJW helped reduce diarrhea and damage to the intestines caused by irinotecan. While irinotecan increased levels of inflammatory cytokines and caused intestinal cell death, SJW helped lower these effects—especially by reducing TNF-α levels and intestinal cell death between days 5 and 11. In conclusion, it was found that SJW may help protect the gut from chemotherapy-related side effects by reducing inflammation and preventing damage to intestinal cells. More research is needed to see if SJW can be safely used alongside chemotherapy in cancer patients.¹³

Study III: Protein Kinase C Inhibition

The chemotherapy drug CPT-11, which blocks the enzyme topoisomerase I, is being tested in early-stage clinical trials to treat patients with recurrent malignant gliomas (a type of brain tumor). Other drugs known as Protein Kinase Inhibitors (PKC inhibitors), like high-dose tamoxifen and hypericin, have also been used to treat this cancer. This study looked at whether PKC inhibitors could make CPT-11 work better by increasing its ability to kill cancer cells. The results showed that using CPT-11 or its active form (SN-38) along with a PKC inhibitor slowed down tumor cell growth and increased cell death. ¹⁴

Since St. John’s Wort extract (SJWE) is known to strongly inhibit PKC, researchers believe that combining SJWE with CPT-11 could improve its anti-cancer effects. Another study that combined SJWE with a different chemotherapy drug, temozolomide, also showed encouraging results, suggesting the combination may be more effective than either treatment alone.¹⁵

Reframing the Clinical Perspective

Although SJW at higher doses—particularly extracts with high hyperforin content—may reduce drug plasma levels, no studies have demonstrated that SJW diminishes the antitumor effects of irinotecan. Beyond reducing toxicity and side effects, SJW may provide additional anti-tumor benefits and reduce treatment resistance.

Antitumor Properties and Synergistic Effects

The potent antitumor properties of Hypericum perforatum and its principal bioactive constituent hyperforin (HPF) have been extensively researched and documented. Beyond its established antidepressant role, SJW demonstrates significant anticancer potential through multiple mechanisms. Clinical evidence shows SJW reduces colorectal cancer risk in humans while preventing carcinogen-induced damage in experimental models. In established tumors, SJW and HPF effectively target cancer hallmarks by suppressing inflammatory pathways, inhibiting pro-survival kinases, blocking angiogenesis, and preventing extracellular matrix degradation.

HPF’s unique physicochemical properties—high lipophilicity and mild acidity—enable critical antitumor actions. As a protonophore, HPF disrupts mitochondrial membrane potential, reducing reactive oxygen species (ROS) production and inhibiting cancer cell proliferation. Additionally, HPF reverses characteristic pH dysregulation in tumor cells by facilitating proton re-entry across plasma membranes. At higher concentrations, SJW/HPF trigger mitochondrial apoptosis in malignant cells.

Notably, emerging evidence suggests SJW/HPF may synergize with conventional chemotherapeutics by sensitizing resistant cancer cells, reducing treatment-related side effects, and enhancing drug delivery to tumor sites. This multifaceted profile positions SJW/HPF as promising candidates for both cancer prevention strategies and adjunctive treatment approaches in integrative oncology settings.¹⁶

SJWE has also demonstrated profound anti-cancer effects, including selective anti-angiogenic capacity.¹⁷

“Our data indicates that hyperforin is a compound that interferes with key events in angiogenesis, confirming the recent and growing evidence about a potential role of this compound in cancer and metastasis inhibition and making it a promising drug for further evaluation in the treatment of angiogenesis-related pathologies.“¹⁸

Clinical Interpretation Considerations

Upon careful examination of available data, while SJWE can decrease blood levels of certain medications, the extent to which this translates to decreased effectiveness remains unclear. Many studies appropriately use qualifying terms such as “may” or “suggest.” It is possible that SJWE decreases blood levels without reducing effectiveness, while simultaneously decreasing side effects, improving tolerability, and potentially enhancing response rates through its pleiotropic anti-cancer effects.

Safety and Dosage Recommendations

To minimize unnecessary drug safety risks during co-medication therapy, SJW extracts with low to medium hyperforin levels should be prescribed to patients experiencing depressive episodes. Current recommended daily SJW intake ranges from 300-1800 mg. Since higher SJW doses do not produce more pronounced antidepressant effects, products with lower extract doses (300-900 mg daily range) should be preferentially recommended to minimize safety risks.¹⁹

Conclusion

St. John’s Wort is a power herb with many potential benefits, especially when used in combination with certain cancer treatments. It contains a variety of natural compounds, like hyperforin, that can help reduce inflammation, support the immune system, and even kill cancer cells.

Studies show that it may reduce side effects from chemotherapy, such as diarrhea and damage to healthy cells, and possibly improve the overall effectiveness of cancer drugs. However, it’s also clear that St. John’s Wort can change how the body processes medications, sometimes lowering their levels and making them less effective—especially when extracts are high in hyperforin. Because of this, it’s important to use caution, especially with drugs like cyclosporine used in transplant patients. The safest way to use St. John’s Wort may be in lower doses with low-hyperforin extracts, which still offer benefits but reduce the risk of dangerous interactions. With careful guidance from a qualified healthcare provider, St. John’s Wort can play a helpful role in balanced cancer care by reducing side effects, supporting mental health, and improving treatment outcomes.